Suven Life Sciences Ltd.
NSE: SUVEN | BSE: 530239
₹267.85
₹3.40
(1.29%)
As on 10-Jun-2026 15:09IST
Market cap
₹7,058 Cr
Revenue (TTM)
₹7 Cr
P/E Ratio
--
P/B Ratio
11.9
Div. Yield
0 %
Quality Score
1/10
Growth Score
5/10
Valuation Score
2/10
Momentum Score
9/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹-276 Cr
-
ROE
-84.9 %
-
ROCE
-84.5 %
-
Industry P/E
46.12
-
EV/EBITDA
-24.8
-
Debt to Equity
0
-
Book Value
₹22.4
-
EPS
₹-12
-
Face value
1
-
Shares outstanding
263,720,583
10 Years Aggregate
CFO
₹-549.70 Cr
EBITDA
₹-322.96 Cr
Net Profit
₹-413.63 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Suven Life
| 61.1 | 20.1 | 97.1 | 20.6 | 64.4 | 24.4 | 11.3 |
|
BSE Healthcare
| 8.2 | 1.0 | 8.3 | 8.0 | 24.8 | 13.5 | 12.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Suven Life
| 30.0 | 55.7 | 18.0 | -16.6 | -2.4 | -70.5 | 32.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Suven Life
|
267.9 | 7,058.5 | 7.1 | -276.3 | -4,077.5 | -63.3 | -- | 11.9 |
| 1,034.7 | 12,636.6 | 2,551.8 | 564.5 | 28.3 | 18.4 | 22.4 | 3.8 | |
| 470.1 | 8,290.8 | 947.3 | 247.8 | 28.5 | 18.9 | 33.5 | 6.1 | |
| 1,321.8 | 14,069.3 | 1,054.9 | 256.3 | 27.8 | 13.7 | 53.9 | 7.0 | |
| 1,727.5 | 33,467.3 | 9,203.5 | 941.3 | 15.4 | 19.6 | 36.2 | 6.8 | |
| 386.3 | 4,274.7 | 165.8 | 46.7 | 37.8 | 16.9 | 91.6 | 14.9 | |
| 129.8 | 3,854.0 | 2,319.1 | 137.6 | 8.1 | 8.2 | 28 | 2.1 | |
| 16,999.0 | 21,896.5 | 2,023.0 | 364.0 | 23.9 | 20.8 | 60.2 | 11.7 | |
| 852.8 | 4,365.9 | 811.3 | 21.0 | 0.7 | 2.1 | 212.5 | 3.4 | |
| 1,110.1 | 5,188.4 | 649.5 | 121.6 | 23.7 | 13.2 | 45 | 5.6 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Suven Life
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and... internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist for treating sleep and cognitive disorders; and Ropanicant (SUVN-911), an Alpha4Beta2 nAChRs receptor antagonist for the treatment of depressive disorders. The company is also developing Usmarapride (SUVN-D4010), a bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for treating cognitive disorders; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for treating gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is based in Hyderabad, India. Suven Life Sciences Limited operates as a subsidiary of Jasti Property and Equity Holdings Private Limited. Read more
-
Incorporated
1989
-
Chairman
Venkateswarlu Jasti
-
Managing Director
Venkateswarlu Jasti
-
Headquarters
Hyderabad, Telangana
-
Website
Looking for more details about Suven Life Sciences Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
Quarterly Updates
Annual Reports
Announcements
View AnnouncementsRectification Order For Assesment Year 2020-21
29-May-2026Clarification On Volume Movement Letter
19-May-2026No News & Announcements are available.
FAQs for Suven Life
What is the current share price of Suven Life Sciences Ltd Today?
The share price of Suven Life Sciences Ltd is ₹267.85 (NSE) and ₹267.95 (BSE) as of 10-Jun-2026 15:09 IST. Suven Life Sciences Ltd has given a return of 64.43% in the last 3 years.
What is the current PB & PE ratio of Suven Life Sciences Ltd?
Since, TTM earnings of Suven Life Sciences Ltd is negative, P/E ratio is not available.
The P/B ratio of Suven Life Sciences Ltd is 11.94 times as on 10-Jun-2026, a 253 premium to its peers’ median range of 3.38 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
22.75
|
|
2024
|
0.00
|
8.05
|
|
2023
|
0.00
|
2.82
|
|
2022
|
0.00
|
14.02
|
|
2021
|
0.00
|
12.61
|
What is the 52 Week High and Low of Suven Life Sciences Ltd?
The 52-week high and low of Suven Life Sciences Ltd are Rs 299.99 and Rs 124.11 as of 10-Jun-2026.
What is the market cap of Suven Life Sciences Ltd?
Suven Life Sciences Ltd has a market capitalisation of ₹ 7,058 Cr as on 10-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Suven Life Sciences Ltd?
Before investing in Suven Life Sciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.